Bookmarks
ID-427: Detecting and treating CKD at the earliest stages
Safe People
Organisation name
Imperial College Healthcare NHS Trust
Applicant name(s)
Rakesh Dattani
Funders/ Sponsors
Safe Projects
Project ID
ID-427-2
Lay summary
This study’ll evaluate the effectiveness & health benefits for patients prescribed with SGLT2 inhibitors in the earliest phases of being diagnosed with CKD, to assess their impact and understand the true benefits of this class of drugs for CKD patients.
Public benefit statement
CKD affects thousands of patients within NWL, and most harm from CKD is found when not diagnosed or treated at the earliest stages. Without effective early treatment, CKD can cause serious harm, such as rapid decline in kidney function, as well as associated cardiovascular complications. Most serious complications include end-stage kidney failure treatment. It is generally accepted that the earlier that this treatment is commenced the greater the benefit for the individual and on a population level the greater the benefit for the NWL health services. However, there requires more evidence-based research to determine how effective treatments are, such as SGLT2 inhibitors. This study will evaluate the effectiveness and health benefits for patients prescribed with SGLT2 inhibitors in the earliest phases of being diagnosed with CKD, to assess their impact and understand the true benefits of this class of drugs for CKD patients.
Other approval committees
Project start date
17/10/2024
Project end date
31/05/2026
Latest approval date
28/02/2026
Safe Data
Dataset(s) name
Data sensitivity level
De-Personalised
Release/Access date
23/02/2026
Safe Setting
Access type
TRE